Summary of Biofrontera Q2 2026 Earnings Call

1Key Financial Results and Metrics

Net Product Revenue: $12 million, a 33% increase year-over-year.

Gross Margin: Approximately 80%, up from 71% in Q2 2025.

Adjusted EBITDA: Breakeven at $200,000, a significant improvement from a loss of $5.1 million in Q2 2025.

First Half Revenue: $22.1 million, a 25.4% increase from $17.6 million in the same period last year.

Net Loss: $0.6 million ($0.05 per share), improved from a loss of $5.3 million ($0.57 per share) in Q2 2025.

Cash Position: $4.7 million as of June 30, 2026, down from $6.4 million at the end of 2025.

2Strategic Updates and Business Highlights

The company experienced its strongest Q2 and first half as a standalone U.S. business, attributed to a growing commercial organization and disciplined expense management.

The strategic acquisition completed in October 2025 allowed Biofrontera to gain full ownership of U.S. rights for Ameluz and RhodoLED, improving revenue structure.

The company is focused on expanding its clinical pipeline, with upcoming FDA submissions for superficial basal cell carcinoma (sBCC) and actinic keratosis (AK) treatments.

3Forward Guidance and Outlook

Anticipated FDA approval for sBCC by September 28, 2026, with a full launch expected in Q1 2027.

Plans to file a supplemental NDA for AK label expansion by the end of Q3 2026, targeting a larger patient base.

The company aims to achieve cash flow breakeven in 2026, supported by revenue growth and potential milestone payments.

4Bad News, Challenges, or Points of Concern

ITC Ruling: A final determination by the International Trade Commission (ITC) restricts the sale of the RhodoLED XL lamp and Ameluz for use with this lamp, affecting future sales.

The company is implementing a remediation plan to modify the XL lamp, which requires FDA approval and may delay sales.

The ongoing litigation and the need for a new lamp design could pose risks to revenue expectations and operational focus.

The company has included a going concern qualification in its financial statements, indicating potential liquidity risks.

5Notable Q&A Insights

Management confirmed that the remediation plan involves minor design changes to the XL lamp, which will still require FDA approval.

Customers with the XL lamp can use existing Ameluz inventory, but new sales for that combination are restricted.

The company is optimistic about maintaining revenue expectations despite the ITC ruling, as many customers stocked up on inventory prior to the order's effective date.

The sales force is preparing for the sBCC launch, focusing on marketing materials and reimbursement strategies. Overall, Biofrontera reported strong financial performance in Q2 2026, but faces significant challenges due to regulatory restrictions impacting its product offerings. The company remains focused on growth through clinical advancements and strategic management of its operational constraints.